An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Slides:

Advertisements

Similar presentations

순환기 내과 R3 임규성 Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.

Advertisements

REVEAL Registry PAH Risk Score Calculator

Pulmonary arterial hypertension due to pulmonary veno-occlusive disease in systemic sclerosis: Importance of early diagnosis and cautious use of pulmonary.

Guideline for approaching the differential diagnosis of pulmonary hypertension. CHD, congenital heart disease; CO, cardiac output; CT, contrast-enhanced.

Kaplan–Meier survival curves of interstitial pneumonia with autoimmune features (IPAF) with usual interstitial pneumonia (UIP) pattern (on high-resolution.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

a) Normal parasternal long-axis view.

Radiology assessment of pulmonary amyloidosis

Cohort identification and exclusion.

A 45-year-old with pulmonary hypertension

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Severe pulmonary hypertension (PH) in interstitial lung disease (ILD) stepwise composite echocardiographic score. Severe pulmonary hypertension (PH) in.

Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

REVEAL pulmonary arterial hypertension (PAH) risk score.

Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.

Timeline of approval of therapies for pulmonary arterial hypertension.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018 Stephan Rosenkranz, Irene.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

A pump function graph demonstrating mean right ventricular pressure as a function of stroke volume (SV). A pump function graph demonstrating mean right.

Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Conceptual model of the ageing Fontan circulation

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Change in physiological variables from baseline values a) at rest and b) during exercise after saline infusion and exposition to different β-blocker agents.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

A) Small pulmonary arteries within a fibrotic area (usual interstitial pneumonia lung). a) Small pulmonary arteries within a fibrotic area (usual interstitial.

Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at two different levels of pulmonary vascular resistance (PVR). Mean pulmonary.

An algorithm for investigating pulmonary hypertension (PH) using echocardiography. An algorithm for investigating pulmonary hypertension (PH) using echocardiography.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Use of high-resolution computed tomography imaging to diagnose different connective tissue disease-associated interstitial lung diseases (ILDs), and to.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Procedure for the diagnosis of interstitial lung diseases.

Distribution of diffusing capacity of the lung for carbon monoxide (DLCO) among 243 scleroderma patients who underwent right heart catheterisation (RHC)

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

A–c) Chest computed tomography excluding acute lung embolism and parenchymal lung disease and d–g) echocardiography performed during diagnostic work-up.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Relationship between pulmonary vascular obstruction (PVO) and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension (CTEPH) and.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Schematic diagram of the DETECT study [56].

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; PAP: pulmonary artery pressure; PA: pulmonary artery; BNP: B-type natriuretic protein; lcSSc: limited cutaneous systemic sclerosis; DL,CO: diffusing capacity of the lung for carbon monoxide; RVH: right ventricular hypertrophy; PO2: oxygen tension; TR: tricuspid regurgitation; CT: computed tomography; PE: pulmonary embolism; PF: pulmonary fibrosis; V′/Q′: ventilation/perfusion ratio; ILD: interstitial lung disease; mPAP: mean PAP; PVR: pulmonary vascular resistance; CCB: calcium channel blockers; WHO: World Health Organization; ETRA: endothelin receptor antagonist; PDE: phosphodiesterase. Reproduced from [110] with permission from the publisher. Joshua J. Solomon et al. Eur Respir Rev 2013;22:6-19 ©2013 by European Respiratory Society